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Abstract: 
Identification of transcription factors expressed by differentiated cells is informative not only 
of tissue-specific pathways, but to help identify master regulators for cellular reprogramming. 
If applied, such an approach could generate healthy autologous tissue-specific cells for 
clinical use where cells from the homologous tissue are unavailable due to disease. Normal 
human epithelial cells of buccal and urothelial derivation maintained in identical culture 
conditions that lacked significant instructive or permissive signalling cues were found to 
display inherent similarities and differences of phenotype. Investigation of transcription 
factors implicated in driving urothelial-type differentiation revealed buccal epithelial cells to 
have minimal or absent expression of PPARG, GATA3 and FOXA1 genes. Retroviral 
overexpression of GATA3 or PPARG1 coding sequences in buccal epithelial cells resulted in 
nuclear immunolocalisation of the respective proteins, with both transductions also inducing 
expression of the urothelial differentiation-associated claudin 3 tight junction protein. 
33$5ȖRYHUH[SUHVVLRQalone entrained expression of nuclear FOXA1 and GATA3 proteins, 
providing objective evidence of its upstream positioning in a transcription factor network and 
identifying it as a candidate factor for urothelial-type transdifferentiation or reprogramming. 
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Introduction: 
The urinary tract from the renal pelvis, through ureters, bladder and proximal urethra is lined 
intra-luminally by urothelium: a transitional epithelium. Urothelium derives from two 
embryological sources: bladder urothelium is endodermally-derived from the urinogenital 
sinus, whereas ureteric urothelium is of mesodermal (Wolffian duct) origin (Tanaka et al., 
2010). Both urothelia share common features of form and function, with stratification into 
basal, intermediate and the highly-specialised lumen-facing superficial cells that constitute 
the main urinary barrier. Superficial cells are characterised by apical expression of tissue-
restricted transmembrane uroplakins that contribute to transcellular barrier function (Deng et 
al., 2002; Sun et al., 1996), whilst paracellular barrier function is provided by well-developed 
intercellular tight junctions (Van Itallie and Anderson, 2014; Varley et al., 2006). In human 
urothelium, expression of claudin 3 is implicated functionally in the terminal tight junction 
(Smith et al., 2015). Not only does urothelium form one of the tightest barriers in the body, 
but despite being mitotically-quiescent in the normal state, it is one of the most rapidly 
repairing of all mammalian tissues (reviewed by Khandelwal et al., 2009). The mechanism(s) 
involved in regulating the balance between urothelial differentiation and regeneration 
represent a paradox with major implications for urological practice.  
 
There is a clinical need to reconstruct the lower urinary tract in patients with end-stage 
bladder diseases, including cancer (reviewed by Garriboli et al., 2014). In current surgical 
practices where the bladder is reconstructed with bowel (enterocystoplasty or cystectomy 
with urinary diversion using bowel), the large majority of complications arise from the 
incompatibility of bowel epithelium to long-term urine exposure (Froehner et al., 2009; 
Hautmann et al., 2006; Kälble et al., 2011). Alternative tissue engineering strategies for 
bladder replacement and lower urinary tract reconstruction are at different stages of 
development and translation (Adamowicz et al., 2017; Lam Van Ba et al., 2015; Turner et al., 
2011). In all approaches, the need for a functional urinary barrier is paramount to avoid 
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serious clinical complications. $VDSDWLHQW¶VRZQurothelium may be compromised by 
disease or the disease environment (Subramaniam et al., 2011), the ability to generate 
urothelium from induced pluripotent or other autologous cells is an essential, albeit future 
goal. 
 
We have previously described a cell culture system for propagating normal human urothelial 
(NHU) cells in low calcium, serum-free medium (Southgate et al., 1994). In these conditions, 
urothelial cells lose expression of archetypical transitional epithelial markers (including 
cytokeratin (CK) 13, differentiation-restricted CK20 and most uroplakin genes) and adopt a 
more primitive or ³basal-like´EGFR-autocrine-regulated CK14-positive squamous epithelial 
cell phenotype (Varley et al., 2005). Such cells retain capacity for urothelial-type 
differentiation, inducible either by ligand-activation of PPARȖ (Varley et al., 2004b, 2004a, 
2009), or by growth in serum (Cross et al., 2005). Applied to bladder or ureteric human 
urothelial cells, both methods promote a common network of transcription factors (TFs) 
(Böck et al., 2014) that further induce the differentiation-associated expression of urothelial 
cytokeratins, tight junction claudins and uroplakins (Varley et al., 2004b, 2004a, 2006). 
Specified TFs of the network, including interferon regulatory factor 1 (IRF1), forkhead box 
protein A1 (FOXA1), E74-like factor 3 (ELF3) and GATA Binding Protein 3 (GATA3), have 
been verified to have a functional role in transactivating the downstream differentiation-
associated genes (Böck et al., 2014; Fishwick et al., 2017; Varley et al., 2009). Further 
evidence of a causal influence on urothelial programming is the finding that many of these 
same TF genes are implicated in urothelial cancer (Choi et al., 2014; Eriksson et al., 2015; 
The Cancer Genome Atlas Research Network, 2014).  
 
It is axiomatic that the precise nature of the transcription factor networks will specify the 
differentiated phenotype. Therefore, we sought to identify key urothelium-determining TFs by 
comparing to oral epithelial cells from buccal mucosa. We proposed to use the identified 
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constitutive differences in TF expression to perform a preliminary investigation into the 
influence of ectopic TF expression on the interconversion of oral epithelial into urothelial 
cells. As in other systems, where a transdifferentiation approach has informed the master 
cell type regulators (eg myogenic differentiation (MyoD) (Davis et al., 1987)), such an 
approach is predicted to identify the key factors required for urothelial conversion from 
pluripotent stem cell sources. 
 
Materials and Methods: 
Tissue Samples 
The collection and use of human tissues for research was covered by NHS Research Ethics 
Committee approvals, with patient informed consent as required. Buccal mucosa tissue 
samples were obtained as trimmings from male patients (age 3-65) undergoing urethral 
repair surgery. Urothelial samples (from renal pelvis or ureter) were obtained from 
anonymous male and female donors (age 1-79 years) undergoing a variety of urological 
procedures, including uninvolved urothelial tissue distal to renal cell carcinoma. Histological 
analysis on representative fragments was performed to check that all tissue samples were of 
normal morphology.   
 
Cell Culture 
Normal human buccal epithelial (NHB) cells and normal human urothelial (NHU) cells were 
isolated as described (Oda and Watson, 1990; Southgate et al., 1994) respectively. In brief, 
to isolate NHB cells, first the epithelium was separated from the underlying connective tissue 
by incubation in 0.5 % (w/v) Dispase II (Roche) at 37 oC for 3-4 hours. The epithelium was 
dissected into small pieces with scissors and the cells dissociated by incubation in a trypsin-
EDTA solution at 37 oC for 5 minutes. For NHU cell isolation, tissue samples were incubated 
in an EDTA containing solution for 4 hours at 37 oC. The epithelium, following separation 
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from the underlying connective tissue using forceps, was incubated in 100 U/ml collagenase 
(type IV) for 20 min at 37 oC. Following the isolations, primary NHB and NHU cells were 
cultured identically RQ3ULPDULDplasticware (Corning) in keratinocyte serum-free medium 
(KSFM) containing bovine pituitary extract (BPE) and epidermal growth factor (EGF) 
(Invitrogen) plus 30 ng/ml cholera toxin. NHB and NHU cell cultures were passaged at 
just-confluence and maintained as serially-passaged finite cell lines, as previously described 
for NHU cells (Southgate et al., 1994). Each experiment was performed on one to four 
independent donor cell lines, with a total of 16 independent NHB donor cell lines and 10 
independent NHU donor cell lines used to perform the experiments described herein. The 
number (n) of independent cell lines used for each experiment is provided in the respective 
figure legends. 
 
Urothelial Differentiation Protocols 
Two protocols optimised previously for the differentiation of NHU cells were applied for the 
differentiation experiments reported here; NHU cells cultured identically to the NHB cells 
were included as comparative controls. 
First, to LQGXFHGLIIHUHQWLDWLRQE\33$5ȖDctivation, 70 % confluent epithelial (NHU control or 
NHB) cell cultures were exposed to 1 µM PD153035 (EGFR-TK inhibitor) (Merck Millipore) 
and 1 µM troglitazone (TZ; PPARȖ agonist) (Tocris) for 24 hours, before replacement with 1 
µM PD153035 alone (protocol termed TZ/PD) (Varley et al., 2004a).  
Second, to produce stratified epithelial cell sheets, epithelial (NHU control or NHB) cell 
cultures were grown to 80% confluence and the medium was changed to contain 5% (v/v) 
adult bovine serum (ABS; SeraLab) for five days.  For TEER studies, the cultures were then 
passaged and seeded onto 12 mm, 0.4 µm pore-size Snapwell culture inserts (Corning® 
Costar®).  The insert cultures were established in medium containing 5 % ABS for 24 hours 
and the medium was changed to contain 5 % ABS plus 2 mM [Ca2+] (Cross et al., 2005). 
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Barrier Assessment and Cell Sheet Harvest 
Trans-Epithelial Electrical Resistance (TEER) measurements were taken using chopstick 
STX2 electrodes and an Epithelial Voltohmeter (World Precision Instruments). The average 
TEER of Snapwell culture inserts containing medium only was subtracted from each 
recorded value. To harvest epithelial cell sheets from the Snapwell culture inserts, cell 
sheets were incubated with 2% (w/v) Dispase II (Roche) for 30 minutes at 37 oC. Released 
cell sheets were floated into CellSafe+ biopsy capsules (CellPath) and placed into 
embedding cassettes. The cell sheets were fixed in 4 % formaldehyde for 24 hours, before 
processing into paraffin wax. 
 
Antibodies 
The following primary antibodies were used at the stated titrations for immunoblotting (IB), 
immunofluorescence (IF) and immunohistochemistry (IHC): ȕ-actin (ACTB; Sigma-Aldrich, 
AC-15) (IB ± 1:250,000); claudin 3 (Life Technologies, Z23.JM) (IB ± 1:4000); claudin 4 (Life 
Technologies, 3E2C1) (IB ± 1:1000); claudin 5 (Life Technologies, 4C3C2) (IB ± 1:1000); 
claudin 7 (Life Technologies, ZMD.241) (IB ± 1:1000); cytokeratin 5 (CK5) (Abcam, SP27) 
(IHC ± 1:100); cytokeratin 5 (CK5) (The Binding Site, PH607) (IF ± 1:100); cytokeratin 7 
(CK7) (Novocastra, OV-TL12/30) (IHC ± 1:400, IF ± 1:40); cytokeratin 13 (CK13) (Abnova, 
1C7) (IHC ± 1:500, IF ± 1:500); cytokeratin 14 (CK14) (Serotec, LL002) (IHC ± 1:1200); 
cytokeratin 14 (CK14) (ICRF, LL001) (IF ± 1:5); cytokeratin 20 (CK20) (Novocastra, Kr20.8) 
(IHC ± 1:200); Cytokeratin 20 (CK20) (Cymbus Bioscience, IT-Ks20.3) (IF ± 1:100); ELF3 
(Abcam, EPESER1) (IF ± 1:1000, IB ± 1:20,000); FOXA1 (Santa Cruz Biotechnology, Q-6) 
(IF ± 1:200, IB ± 1:500); FOXA1/2 (Santa Cruz Biotechnology, C-20) (IF ± 1:200); GATA3 
(Cell Signaling, D13C9) (IF ± 1:800, IB ± 1:1000); PPARG (Cell Signaling, D69) (IF ± 1:100, 
IB ± 1:500).  
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Immunohistochemistry (IHC) 
5 µm sections were dewaxed through xylene into ethanol. Antigen retrieval was performed 
by boiling the slides in 10 mM citric acid buffer (pH 6.0) for 10 minutes. For some antibodies 
(CK13 and CK14), cell sheets were incubated in 0.1 % trypsin at 37 oC prior to the citric acid 
incubation. Sections were blocked using an avidin/biotin blocking kit (Vector Laboratories) 
and 5 % rabbit or goat serum (as determined by the secondary antibody), incubated with 
primary antibody at 4 oC overnight, then washed. A biotinylated secondary antibody was 
applied to the cell sheets, followed by a streptavidin-biotinylated/horseradish peroxidase 
complex (Vector Laboratories), before visualisation with diaminobenzidine (Sigma Aldrich). 
The cell sheets were counterstained lightly with haematoxylin, dehydrated and mounted in 
DPX (CellPath). Appropriate methodology, specificity and negative controls were included 
for each antibody. 
 
Reverse Transcribed-Polymerase Chain Reaction (RT-PCR) and quantitative RT-PCR (RT-
qPCR). 
Cell cultures were solubilised using TRIzol5HDJHQWDQG51$H[WUDFWLRQZDVSHUIRUPHG
using a phenol-chloroform and isopropanol precipitation method according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV(Invitrogen). Any contaminating genomic DNA was removed by 
DNase digestion (DNA-IUHH, Ambion) and checked using RT-negative controls. cDNA was 
synthesized from 1 µg of total RNA using the first-strand synthesis system primed with 
random hexamers (Invitrogen). RT-PCR and RT-qPCR were performed as described 
previously (Böck et al., 2014). A list of PCR primers is provided in Table 1. RT-qPCR was 
performed using three technical replicates for each gene.  RT-PCR was performed using 30 
cycles except for GAPDH (25 cycles).  
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Immunoblotting 
Whole protein lysates were generated from cell cultures using a reducing 2x SDS lysis buffer 
containing 1% protease inhibitor (Sigma-Aldrich). Lysates were incubated on ice for 
30 minutes and centrifuged at 20,000 g for 30 minutes at 4 oC. 25 µg was loaded into either 
4-12 % bis-Tris gels or 3-8 % Tris-acetate gels (Novex®) and electrophoresis was performed 
at 200 V for 1 hour. Proteins were transferred to an Immobilon-FL 0.45 µm PVDF membrane 
by electroblotting. Membranes were blocked using Odyssey Blocking Buffer (Li-Cor) and 
incubated with the primary antibody overnight at 4 oC. The fluorescent secondary antibody 
was applied to the membrane for 1 hour at ambient temperature, and membranes were 
imaged for semi-quantification using an Odyssey® infrared imaging system (Li-Cor). 
 
Immunofluorescence Microscopy 
Cells were cultured on 12-well glass slides (C A Hendley Essex Ltd), fixed in 4 % 
formaldehyde for 10 minutes and permeabilised with 0.1 7ULWRQ;-100 (Sigma Aldrich), 
before incubation with primary antibody in a 0.1% BSA solution overnight at 4 oC. A 
fluorescent-conjugated secondary antibody was applied to the cells for 1 hour at ambient 
temperature, before further washing and counterstaining of nuclei with 0.1 µg/ml Hoechst 
33258 (Sigma Aldrich). 
 
Overexpression of GATA3 and PPARG1 in NHB cells by Retroviral Transduction 
Sequences for GATA3 (CCDS31143) and PPARG1 (CCDS2610) were cloned into the 
retroviral vector, pLXSN (Clontech) and confirmed by sequencing. pLXSN-GATA3 and 
pLXSN-PPARG1 plasmids were transfected into retroviral packaging cells (PT67 cells) 
(Clontech), and selected with G418. Successfully transfected PT67 cells were grown to 
confluence and the generated retrovirus was collected in the medium. NHB cells were 
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transduced with the retrovirus and successfully transduced epithelial cells were selected 
using antibiotics. Control NHB cells were transduced with the pLXSN vector only (Empty). 
 
Statistical Analysis 
Statistical analysis was performed where appropriate using either a two-tailed, paired t-test 
or a one-way ANOVA with post-test. Error bars represent standard deviation.  
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Results 
Comparison of Human Urothelial and Buccal Epithelial Phenotypes In Situ and In Vitro.  
In situ, the epithelium of buccal mucosa is a non-cornified stratified squamous epithelium 
that can average 30 cell layers thick. By contrast, the urothelium, a transitional epithelium, 
averages 4-5 cell layers. Immunohistochemical examination of CK5, CK7, CK13, CK14 and 
CK20 revealed expression of CK5 in all layers of buccal epithelium and an absence of CK7 
and CK20 expression. CK13 expression was suprabasal, whilst CK14 was particularly 
intense but not exclusive to the basal layers of buccal epithelium (Fig. 1A). In urothelium, 
CK5 and CK13 were associated with the basal layers, CK7 was present in all layers, CK14 
was absent and CK20 was confined to the superficial cell layer (Fig. 1B). 
 
When isolated and maintained in identical low calcium [0.09 mM] serum-free culture 
conditions (Fig. 1C), both NHU and NHB cells formed proliferative, contact-inhibited 
monolayer cultures that upon reaching confluence could be serially sub-cultured up to 10 
times (data not shown). The in vitro expression of cytokeratin proteins by both cell types was 
similar by immunocytochemistry, with CK5, CK7, CK13 and CK14 detected, including gain of 
CK7 by NHB cells and gain of CK14 by NHU cells; CK20 was not expressed (Fig. 1D). 
 
Generation of Cell Sheets and Measurement of Barrier Function 
Using a protocol optimised for differentiated barrier induction by NHU cells in vitro (Cross et 
al., 2005), NHB cultures formed multi-layered cell sheets that were similar morphologically to 
those achieved by NHU cells cultured in identical conditions (Fig. 2A). Using TEER to 
assess barrier function, NHB cell sheets were unable to form a tight barrier (defined here as 
 kFP2)FRPSDUHGWRW\SLFDOEDUULHUVIRUPHGE\1+8FHOOVRIWRNȍFP2 (Fig. 2B). 
Immunohistochemical analysis of cytokeratin expression in NHB cell sheets demonstrated 
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consistent expression of CK5 and CK14 throughout all layers, with CK13 limited to the upper 
portion of the cell sheets, and diffuse, weak CK7 expression (Fig. 2C). By contrast, NHU cell 
sheets were CK7-positive throughout all cell layers and demonstrated reciprocal patterns of 
CK5 and CK13, but were negative for CK14. 
 
Expression of Uroplakin (UPK) Genes by NHB Cells In Vitro 
Uroplakin transcript expression was evaluated initially by RT-PCR in control NHB cell 
cultures and following combined TZ/PD treatment (Fig. S1) (Varley et al., 2004a). NHB cells 
showed robust expression of UPK1B and UPK3B, with equivocal expression of UPK1A and 
UPK2 appearing at later (confluence-associated) time-points in both baseline and induced 
conditions (Fig. S1). These results were confirmed by RT-qPCR in three independent NHB 
donor cell lines, where NHB cells were shown to express transcripts for UPK1A, UPK1B, 
UPK2 and UPK3B (Fig. 3A). The expression of UPK2 and UPK3B transcripts by NHB cells 
was significantly upregulated at 72 hours following combination TZ/PD therapy (Fig. 3A). 
Expression of UPK3A was absent in NHB cells. 
 
Expression of Urothelial Differentiation-Associated Transcription Factors by NHB Cells In 
Vitro. 
Based on the clear phenotypic differences observed between the two cell types in vitro, 
RT-PCR was used to evaluate expression of seven transcription factor genes (ELF3, 
FOXA1, GATA3, GRHL3, KLF5, IRF1 and PPARG) implicated in urothelial development 
and/or differentiation (Bell et al., 2011; Böck et al., 2014; Varley et al., 2004b, 2004a, 2006, 
2009; Yu et al., 2009) (Fig. 3B&C). NHB cells showed absent or barely-detectable 
expression of FOXA1, GATA3 and PPARG transcripts even following attempts using TZ/PD 
to initiate differentiation in case of a positive feedback loop.  Expression of GRHL3, IRF1 and 
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KLF5 appeared constitutive in nature, while ELF3 expression was upregulated in response 
to TZ/PD. 
RTqPCR analysis of three independent NHB donor cell lines confirmed the results obtained 
by RT-PCR, demonstrating weak expression of FOXA1, GATA3 and PPARG, with significant 
upregulation only of ELF3 transcript following TZ/PD treatment (Fig. 4A). Similar results were 
obtained by evaluating protein expression by western blotting (Fig. 4B). By 
immunofluorescence microscopy, ELF3, FOXA1/2, GATA3 and PPARȖ were weak/absent 
in NHB cells treated with combined TZ/PD, contrasting to the typically strong nuclear protein 
expression seen when NHU cells were subjected to identical conditions in vitro (Fig. 4C).  
 
NHB overexpression studies. 
To further investigate transcription factor regulation and hierarchies, GATA3 and PPARG1 
were selected to stably overexpress in NHB cells due to their low/absent expression in NHB 
cells and known expression and importance in urothelial differentiation. PPARG1 was 
selected over PPARG2 due to previous evidence suggesting that PPARȖ1 is the primary 
PPARG isoform required for urothelial cell-type differentiation (Strand et al., 2013). 
GATA3  
Successful overexpression of GATA3 was achieved in NHB cells and resulting in nuclear 
immunolocalisation (Fig. 5A&B). Overexpression of GATA3 did not cause any noticeable 
effect on FOXA1 or PPARȖ1 protein expression in NHB cells, as shown by both western 
blotting and immunofluorescence microscopy (Fig. 5A&B). This remained true even following 
attempts to activate PPARȖ by combined TZ/PD treatment. Expression of tight junction-
associated proteins was examined when transduced NHB cells were induced to form cell 
sheets using 5% bovine serum and 2 mM [Ca2+]. A clear upregulation of claudin 3 protein 
expression was observed following GATA3 overexpression in NHB cells (Fig. 5C). 
Expression of other urothelium-associated tight junction proteins, claudins 4, 5 and 7 were 
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expressed consistently in both control (Empty vector) and GATA3 overexpressing NHB cells. 
GATA3 overexpression, and subsequent Claudin 3 upregulation, failed to result in the gain 
of barrier function by NHB cells sheets, as measured by TEER (81.74 ± 2.35 ÂFP2, Day 4, 
n=3; Control: 110.36 ± 3.54 ÂFP2, Day 4, n=3). 
PPARG1  
Overexpression of PPARG1 in NHB cells caused a noticeable increase in FOXA1 protein 
expression by western blotting (Fig. 6A), although this was not significant when quantified 
across transductions in four independent NHB lines (Fig. 6B). GATA3 protein expression 
was poorly detectable by western blotting in PPARG1 overexpressing NHB cells, even 
following attempts to activate PPARȖ using combination TZ/PD treatment. However, by 
immunofluorescence microscopy PPARG1 overexpression resulted in clear de novo nuclear 
ORFDOLVDWLRQRI33$5Ȗ (n=3/3), FOXA1 (n=3/3) and GATA3 (n=2/3) (Fig. 6C). 
Evaluation of tight junction-associated proteins following stratification of transduced NHB 
cells, revealed a significant upregulation of Claudin 3 protein expression (Fig. 7A&B). The 
expression of Claudins 4, 5 and 7 remained consistently expressed in both control (empty 
vector) and PPARG1-overexpressing cells (Fig. 7A). In addition, PPARG1 overexpression 
had no effect on CK14 expression, which was detectable in both control (empty vector) and 
PPARG1 overexpressing NHB cells (Fig. 7C). Finally, PPARG1 overexpression did not 
result in the gain of barrier function in NHB cell sheets, as measured by TEER 
(54.24 ± 2.99 ÂFP2, Day 4, n=3; &RQWUROÂFP2, Day 4, n=2). 
 
  
15 
 
Discussion: 
In this study we have used a different epithelial cell type in experiments aimed at informing 
future strategies for programming autologous cells to generate human urothelium. Our study 
has shown that PPARȖ1 and GATA3 are nuclear factors differentially expressed by human 
urothelial, not buccal, epithelial cells and that when expressed as individual transgenes, 
these factors effect specific changes on buccal epithelial cell phenotype.  
 
Various groups have attempted to generate human urothelial cells from different types of 
stem cells in order to identify a surrogate cell source for autologous bladder tissue 
engineering (reviewed by Chan et al., 2017). The initiating human cell sources investigated 
have included bone marrow-derived mesenchymal stem cells (Tian et al., 2010); adipose-
derived stem cells (Shi et al., 2012); amniotic fluid-derived stem cells (Kang et al., 2014a); 
umbilical cord stem cells (Wu et al., 2013); pluripotent embryonic stem cells (Osborn et al., 
2014); induced pluripotent stem cells (iPSCs) (Kang et al., 2014b; Moad et al., 2013); and 
voided urine cells (Zhang et al., 2008). The inducing method has frequently assumed 
production of unidentified instructive paracrine factors by urothelial or bladder cancer cell 
lines employed in co-culture (Chung and Koh, 2013; Liu et al., 2009; Ning et al., 2011; Tian 
et al., 2010), or via medium-conditioning (Kang et al., 2014a; Moad et al., 2013; Shi et al., 
2012; Wu et al., 2013; Zhao et al., 2014). Collectively, the results suggest that from any 
naïve heterotypic starting population, an unknown proportion of cells will express urothelial 
differentiation-associated genes under permissive conditions. 
 
More systematic attempts have used a two-staged approach in which pluripotent stem cells 
of embryonic (Osborn et al., 2014) or iPSC (Kang et al., 2014b) derivation are first 
differentiated into definitive endoderm cells. This is followed by attempts to direct urothelial 
differentiation using agonists that activate PPARȖ (Osborn et al., 2014) or the retinoic acid 
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receptor (RAR) (Kang et al., 2014b), as candidate nuclear receptors whose activation is 
implicated in urothelial differentiation. 
 
Irrespective of the approach, all above studies have reported qualitatively similar outcomes 
in detecting upregulated epithelial- and urothelial-associated gene expression within the 
emergent population. Fold increases in the expression of uroplakin (UPK) genes has been 
presented as prima facie evidence of urothelial conversion, even though it is well established 
that uroplakin transcripts are expressed by other (non-urothelial) epithelial cell types (Adachi 
et al., 2000; Kanamori-Katayama et al., 2011; Olsburgh et al., 2003; Rudat et al., 2014).  
UPK1B and UPK3B are the least differentiation stage-restricted of the uroplakins in 
urothelium and here, buccal epithelial cells in vitro were shown clearly to express both 
UPK1B and UPK3B transcripts. Transcripts for UPK1A and UPK2, which are more 
differentiation stage-restricted in urothelium, were also, albeit variably, expressed by buccal 
epithelial cells, further establishing that expression of uroplakin gene transcripts alone 
cannot be used to definitively mark urothelium-specific conversion. Only UPK3A expression 
was absent from native buccal epithelial cells in vitro, potentially indicating that UPK3A 
expression could represent a more objective marker of successful (re)programming to 
differentiated urothelium. This study further indicated the absence of CK14 and expression 
of CLDN3 as part of the urothelial signature phenotype. 
 
We have previously shown that maintenance of NHU cells in vitro in a low calcium, 
serum-free medium results in the loss of urothelial phenotype and reversion to a more 
primitive squamous state, accompanied by changes in chromatin organisation (Fishwick et 
al., 2017). Under identical serum-free culture conditions, buccal epithelial cells similarly 
adopt a proliferative, non-stratified CK14+ squamous phenotype. The provision of serum, in 
conjunction with physiological calcium to promote development of intercellular junctions and 
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polarity, led to re-establishment of the original differentiation programmes of urothelial and 
buccal cells, respectively, indicating that despite the apparent plasticity, cultured cells 
SHUKDSVUHWDLQHGDQHSLJHQHWLF³PHPRU\´7KHDGGLWLRQRIVHUXPSURYLGHVDSHUPLVVLYH
environment for differentiation, revealing underpinning differences in epithelial lineage 
programming, with urothelial cells switching to a CK13+ transitional programme, whereas 
buccal epithelial cells maintain the CK14+ stratified squamous programme. 
 
A comparison of TF expression between buccal versus urothelial cells revealed differential 
expression of )2;$*$7$DQG33$5Ȗ,QSUHDGLSRF\WHVOLJDQGDFWLYDWLRQRI33$5Ȗ
protein provokes transactivation of PPARG as a differentiation-inducing positive feedback 
event (Mueller et al., 2002). This led us to investigate whether ligand-induced activation of 
33$5ȖLQZLOGW\SHEXFFDOHSLWKHOLDOFells could alone entrain a urothelial-like differentiation 
response as part of a positive feedback response. However, in the event, it failed to initiate 
H[SUHVVLRQRI33$5Ȗ)2;$RU*$7$IXUWKHUVXSSRUWLQJWKHLGHDWKDWLQKHUHQWor 
programmed differences between cells (rather than perhaps the presence of inducing 
ligands) defines lineage/differentiation potential.  Whereas forced overexpression of GATA3 
DORQHIDLOHGWRKDYHDQ\FOHDULPSDFWRQWKHH[SUHVVLRQRI33$5ȖRU)2;$LQEXFFDO
epithelial cells, forced expression of PPARG1 did promote both FOXA1 and GATA3 
expression, indicating an upstream position in the regulatory network. 
 
The primary function of the urothelium is to act as a barrier to urine and even following 
propagation in vitro, urothelium-derived cells retain the capacity to differentiate to form a 
functional barrier epithelium. We have shown here that when maintained under identical 
serum-containing culture conditions, in vitro-propagated buccal epithelial cells can form a 
stratified epithelial structure, whilst failing to form a functional barrier. The claudins are the 
main functional barrier-determining constituent of the tight junction, and claudin 3, which has 
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been identified previously as a critical tight junction protein required (but not sufficient) for 
urothelial barrier function (Smith et al., 2015), was weakly expressed in wild type buccal 
epithelial cells. Our approach has demonstrated that individual overexpression of GATA3 
and 33$5ȖDUHERWKDEOHWRSURPRWHLQFUHDVHGFODXGLQSURWHLQH[SUHVVLRQLQEXFFDO
epithelial cells, providing circumstantial evidence implicating them in the urothelial 
differentiation and barrier formation programme. 
 
To date, no study has completely defined the conditions or factors required to direct 
pluripotent cells into coherent urothelial cells capable of forming a functional urinary barrier. 
This suggests a need for better criteria to inform and monitor the process of successful 
urothelial cell programming. Here, we have brought some clarity to the order of complex 
endogenous TF relationships likely to be operating in urothelial cells, where there is both 
interplay between TFs at the level of cooperativity and competition for DNA binding, along 
with positive and negative feedback on TF transcription regulation (Fishwick et al., 2017).  In 
conclusion, our results support PPARȖ1 as a key upstream regulator that could constitute a 
component of a minimal transcription factor network required to promote urothelial-type 
differentiation. As buccal epithelial cells were shown to retain constitutive differences of 
phenotype in serum-free (non-permissive) culture conditions, we suggest that PPARG1 
overexpression experiments in (induced) pluripotent cells would be an informative next step 
for the programmed production of urothelial cells for therapy. 
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Table 1. List of primers used for RT-PCR and RT-qPCR. 
Gene  &ŽƌǁĂƌĚƉƌŝŵĞƌ ? ? ?- ? ? ? ZĞǀĞƌƐĞWƌŝŵĞƌ ? ? ?- ? ? ? Use 
ELF3  GTTCATCCGGGACATCCTC GCTCAGCTTCTCGTAGGTC RT-PCR 
ELF3  TCAACGAGGGCCTCATGAA TCGGAGCGCAGGAACTTG RTqPCR 
FOXA1  CAAGAGTTGCTTGACCGAAAGTT TGTTCCCAGGGCCATCTGT RT-PCR 
RTqPCR 
GATA3  TCCAGACACATGTCCTCCCT TGGTGTGGTCCAAAGGACAG RT-PCR 
GATA3  TCTATCACAAAATGAACGGACAGAA TGTGGTTGTGGTGGTCTGACA RTqPCR 
GRHL3  GTGACAAGGGAGCTGAGAGG CAGTCTCTGGCCGAAGGTAG RT-PCR 
IRF1  GCTGGGACATCAACAAGGAT GTGGAAGCATCCGGTACACT RT-PCR 
KLF5  GACACCTCAGCTTCCTCCAG ACTCTGGTGGCTGAAAATGG RT-PCR 
PPARG  AGACAACCTGCTACAAGCCC GGAAATGTTGGCAGTGGCTC RT-PCR 
PPARG  GAACAGATCCAGTGGTTGCAG CAGGCTCCACTTTGATTGCAC RTqPCR 
UPK1A  GGGGTATCTCGTGGTTTGGG CGTAAGGGCTAGGGACGTTG RT-PCR 
UPK1A  CATTCTTGCTGAACCGTTTGTG GTGACCGTGACAGAACTCTCATG RTqPCR 
UPK1B  TTGAAGCCACCGACAACGAT AACAGACAGGCAGAAGAGGC RT-PCR 
UPK1B  CGCTTGCCTTCAGCTTGTG GGCCCTGGAAGCAACGA RTqPCR 
UPK2  CTCCCGCAAGTAAGGAGGT GAAGGATGGGGGAATTGTTA RT-PCR 
UPK2  CAGTGCCTCACCTTCCAACA TGGTAAAATGGGAGGAAAGTCAA RTqPCR 
UPK3A  ATGGGGAGTTCTGATGGGGA TGCTGGAATACACCTCAGCC RT-PCR 
UPK3A  CGGAGGCATGATCGTCATC CAGCAAAACCCACAAGTAGAAAGA RTqPCR 
UPK3B  CCTCCTGCTTCACTCTCTCTGTCT GAAACTGACAATCACGGCAGAA RT-PCR 
RTqPCR 
GAPDH CAAGGTCATCCATGACAACTTTG GGGCCATCCACAGTCTTCTG RT-PCR 
RTqPCR 
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Figure Captions: 
Figure 1. Comparison between buccal epithelium and urothelium in situ and in vitro.   
(A-B) Histological sections showing representative in situ immunolocalisation patterns for 
cytokeratins CK5, CK7, CK13, CK14 and CK20 in (A) buccal mucosa (scale bar Ł 100 µm) 
and (B) urothelium (scale bar Ł 25 µm). 
(C) Representative phase contrast images of NHB and NHU cells grown in vitro. (Scale bar 
Ł 200 µm 
(D) Immunofluorescence microscopy images of cytokeratin CK5, CK7, CK13, CK14, and 
CK20 expression by NHB and NHU cells grown in low calcium, serum-free medium 
(KSFMc). Immunolabelling was performed on n=3 independent NHB cell lines and images 
are representative, although note that CK13+ cells are infrequent in NHU cell cultures grown 
in these non-differentiated conditions. Scale bar Ł 50 µm. 
 
Figure 2. Formation of cell sheets and barrier function. The ability to form a stratified 
barrier epithelium was examined in three independent NHB cell lines, with a representative 
NHU cell line provided for comparison purposes.   
(A) Representative hematoxylin and eosin-stained NHB and NHU cell sheets showing multi-
layered tissue structures formed 7 days post-seeding onto membranes in serum- and 2 mM 
calcium-containing medium. Scale bar Ł 100 µm. 
(B) Trans-epithelial electrical resistance (TEER) measurements taken daily. Day 0 
measurements were taken 24 hours after seeding the cells onto membrane inserts, directly 
before the medium was changed to increase the calcium concentration to 2 mM. 
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(C) Immunohistochemical analysis of NHB and NHU cell sheets for CK5, CK7, CK13 and 
CK14 protein expression. Representative results shown from experiments performed on n=3 
independent NHB cell lines. Scale bar Ł 50 µm. 
 
Figure 3. Comparison of uroplakin and urothelium differentiation-associated 
transcription factor gene expression by NHB and NHU cell cultures. Employing 
SURWRFROVGHYHORSHGWRGLIIHUHQWLDWH1+8FHOOVE\33$5ȖDFWLYDWLRQcell cultures of NHB or 
NHU cells were exposed to 1 µM troglitazone and 1 µM PD153035 (TZ/PD) for 24 hours, 
maintained in 1 µM PD153035 and harvested at 12, 24, 48 and/or 72 hours. Control cultures 
were exposed to vehicle (0.1 % DMSO) alone.  
(A) RTqPCR for three independent NHB cell lines (represented by different symbols), versus 
a single NHU cell line for comparison of uroplakin (UPK1A, UPK1B, UPK2, UPK3A and 
UPK3B) mRNA expression at the 72 hour time-point. All data has been normalised to 
GAPDH expression and is presented relative to the DMSO-treated NHB cells for each gene 
except UPK3A, where the data is shown relative to the DMSO treated NHU cells due to 
absent UPK3A gene expression by NHB cells. BLOD = Below Limit of Detection. Statistical 
analysis was performed using a two-tailed, paired t-test to determine whether TZ/PD 
resulted in any significant change in gene expression in NHB cells.  
UHSUHVHQWV3UHSUHVHQWVP Error bars represent standard deviation 
(B-C) RT-PCR of ELF3, FOXA1, GATA3, GRHL3, IRF1, KLF5 and PPARG mRNA 
expression by (B) NHB cells and (C) NHU cells. RNA was extracted at the 12, 24 and 48 
hour time-points and then DNAase-treated and used to generate cDNA for RT-PCR. GAPDH 
used as an internal loading control. A no-template (H2O) control was included as negative 
control for the PCR reaction and genomic DNA was used as the positive control (+ctrl). No 
product amplified from RT-negative controls (not shown). Experiments were performed on 
n=2 independent NHB donor cell lines and representative results shown. 
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Figure 4. Evaluation of ELF3, FOXA1, GATA3 and PPARG expression in NHB cells.  
RNA and protein were extracted from parallel cultures of NHB and NHU cells at 72 hours 
IROORZLQJH[SRVXUHWRWKH33$5Ȗ-activating TZ/PD protocol, or a vehicle control (0.1% 
DMSO).  
(A) RTqPCR results combined from three independent NHB cell lines (represented by 
different symbols), with a single NHU cell line for comparison.  All data is normalised to 
GAPDH expression and is presented relative to the DMSO-treated NHB cell control for each 
gene. Statistical analysis was performed using a two-tailed, paired t-test to test if TZ/PD 
treatment resulted in any significant change in gene expression in NHB cells. ** represents P 
 0.01. Error bars represent standard deviation. 
(B) Immunoblot of whole cell protein lysates from representative NHB and NHU cell cultures 
following exposure to the TZ/PD protocol, 1 µM PD153035 alone, or vehicle (0.1 % DMSO) 
for 72 hours. ACTB is included as an internal loading control. Experiments performed on n=3 
independent NHB cell lines with similar results. 
(C) Immunofluorescence microscopy of ELF3, FOXA1/2, GATA3 and PPARȖ in 
representative NHB and NHU cell cultures  Images taken at identical exposures to 
demonstrate differences in labelling intensity between the two cell types. Experiments 
performed on n=3 independent NHB donor cell lines with similar results. Scale bar Ł 50 µm. 
 
Figure 5. GATA3 overexpression in NHB cells.  
(A) GATA3 overexpressing and control (empty vector) NHB cell cultures following exposure 
to the 33$5Ȗ-activating TZ/PD protocol for 72 hours. Western blotting of whole protein 
lysates was performed to assess protein expression of GATA3, FOXA1 and PPARG1. NHU 
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cells (non-transduced) and treated with the TZ/PD protocol for 72 hours are shown for 
comparison. 
(B) GATA3 overexpressing and control (empty vector) NHB cells at 72 hours post TZ/PD 
protocol. GATA3, FOXA1 and PPARG protein expression assessed by indirect 
immunofluorescence microscopy. NHU cells (non-transduced; 72 hour TZ/PD protocol) were 
included as positive controls for comparison. Scale bar = 50 µm. 
(C) GATA3 overexpressing and control (empty vector) NHB cells were induced to form cell 
sheets using 5 % ABS and 2 mM calcium for up to 7 days. Expression of the tight junction-
associated proteins, Claudin 3, 4, 5 and 7, assessed by western blotting. ACTB was 
included as a loading control. NHU cells (non-transduced) exposed to the same protocol 
were used as a positive control for comparison. 
Experiments were performed on n=2 independent NHB donor cell lines and representative 
results shown.  
 
Figure 6. Evaluation of PPARG, FOXA1 and GATA3 expression in PPARG1 
overexpressing and control (empty) NHB cells. PPARG1 overexpressing and control 
(empty vector) NHB cell cultures were exposed to the TZ/PD protocol for 72 hours. 
Experiments performed on between 2 to 4 independent NHB cell lines (as stated below), 
with representative results shown.  
(A) PPARG1, FOXA1 and GATA3 protein expression assessed by western blotting. ACTB 
expression included as internal loading control. Protein lysates from cell lines known to 
express the proteins of interest were included as positive controls for each antibody (CTRL). 
Experiments performed on n=3 independent NHB cell lines. 
(B) Densitometry analysis of FOXA1 protein expression shown relative to control (Empty - 
DMSO) NHB cells. Data is shown as the mean of n=4 independent transduced NHB cell 
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lines. All values normalised to the ACTB expression. Statistical analysis was performed 
using a one-way ANOVA test, but no statistical significance was found (P > 0.05). Error bars 
represent standard deviation. 
(C) Immunofluorescence microscopy evaluating PPARG, FOXA1 and GATA3 protein 
localisation in PPARG1 overexpressing and control (empty vector) NHB cells following the 
TZ/PD protocol at 72 hours. Experiments were performed on n=3 independent transduced 
NHB cell lines. IF images for a single NHB cell line are shown. Nuclear localisation was 
REVHUYHGZLWK33$5ȖQ )2;$Q ), and GATA3 (n=2/3). NHU cells (non-
transduced) treated with the TZ/PD protocol are shown for comparison at the same time 
point. Scale bar = 50 µm.  
 
Figure 7. Assessment of tight junction-associated proteins and CK14 expression in 
PPARG1 overexpressing and control (empty) NHB cells. PPARG1 overexpressing and 
control (empty vector) transduced NHB cells were induced to stratify using serum and 
calcium (detailed in the Methods). Experiments were performed on n=3 independent NHB 
donor cell lines. Results at 7 days shown for a representative transduced NHB cell line. 
ACTB expression used as internal loading control. NHU cells (non-transduced) exposed to 
the same protocol for 5 days are shown for comparison. 
(A) Evaluation of tight junction-associated protein expression by western blotting with 
Claudins 3, 4, 5 and 7. 
(B) Densitometry analysis of claudin 3 expression at day 7 shown relative to control (empty 
vector) cells. All values were normalised to the ACTB expression. Data is shown as the 
mean of n=3 independent transduced NHB donor cell lines. Statistical analysis performed 
using a two-tailed, paired t-WHVWUHSUHVHQWV3Error bars represent standard 
deviation. 
(C) CK14 expression evaluated by western blotting. 
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Supplementary Figure 1. Assessment of uroplakin gene expression by NHB and NHU 
cells in vitro.  
(A-B) RT-PCR of uroplakin (UPK1A, UPK1B, UPK2, UPK3A and UPK3B) mRNA expression 
by (A) NHB and (B) NHU cell lines on RNA extracted at 12, 72 and 144 hours following 
treatment with TZ/PD. GAPDH was included as a housekeeping gene. RNA was digested 
with DNAase to remove any genomic DNA contamination and tested as RT-negative 
controls (not shown). Other shown controls include a no-template (H2O) negative and a 
genomic DNA positive control (+ctrl). Experiments were performed on n=2 independent NHB 
cell lines with similar results. 
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